Peter Wehrwein is the Managing Editor of Managed Healthcare Executive, where he covers a range of topics related to the business and policy aspects of the healthcare industry, with a focus on managed care, pharmacy benefit management, and regulatory issues. His work has also appeared in several other prominent healthcare publications.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Philadelphia, United States (Local)
Peter Wehrwein's coverage suggests a strong focus on healthcare and pharmaceutical topics, often drawing from data and government announcements. Given this emphasis, he is likely to respond well to pitches that provide expert commentary or analysis of new research findings, policy changes in the healthcare sector, or insights into the pharmaceutical industry.
Pitches regarding medical breakthroughs, policy implications for healthcare providers and patients alike, as well as perspectives on upcoming trends in the medical field are likely to resonate with Peter.
As his geographic focus is national (United States), pitches should be tailored accordingly if they involve specific U.S.-focused developments within the healthcare & pharmaceutical landscape.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Peter Wehrwein
Patrick Cooney, president of The Federal Group, a Washington, D.C., lobbying firm says prospects for legislation passing this year, albeit during the post-election lameduck session, are good partly because the PBM legislation would produce Medicare savings that could be put toward other uses.
By: Briana Contreras, Peter Wehrwein
Greg Baker, CEO of AffirmedRx, did not hold back in criticizing CVS Caremark, Optum Rx and Express Scripts and their group purchasing organizations today at the PBMI Annual National Conference.
By: Peter Wehrwein
Patrick Cooney, president of The Federal Group, says elimination of spread pricing is one of the three key elements of the PBM legislation that he believes is likely to pass during the lame-duck session of Congress after the Nov. 5 election.
By: Peter Wehrwein
Kerri Tanner, Pharm.D., the chief pharmacy officer of PayerAlly, says payers are looking for ways to rein in the escalating costs of specialty pharmacy drugs beyond the traditional techniques used by pharmacy benefit managers.
By: Peter Wehrwein
Kerri Tanner, Pharm.D., chief pharmacy officer of PayerAlly, discusses the dynamic pricing models of Waltz Health and Free Market Health as a way for independent specialty pharmacies to compete.
By: Peter Wehrwein
The IQVIA vice president and frequent speaker at pharmaceutical. and managed care meetings shares some insights about phamarcy "deserts" and drug launches. Long, a well-known figure in managed care circles, announced that he is retiring in 2025.
By: Peter Wehrwein
The IQVIA vice president and frequent speaker at pharmaceutical and managed care meetings shares some insights after he delivered the keynote talk at 2024 PBMI Annual National Conference held last week in Orlando, Florida. Long, a well-known figure in managed care circles, announced at the PBMI meeting that he is retiring in 2025.
By: Peter Wehrwein
The IQVIA vice president of industry relations and his talks featuring rapid-fire delivery of voluminous slide decks is a familiar figure in managed care circles. He is retiring in May 2025.
The Minnesota-based PBM is also officially folding Magellan Rx Management into its name. Prime acquired Magellan R in 2022.
By: Peter Wehrwein
The advantage of the glucago-like peptide 1s did not include people who had already developed cirrhosis,
(833) 317-6278 
